感染

订阅

MedSci主页 / 所有栏目 / 感染

ECCMID 2011：感染性疾病机制研究新动态

2011-06-03 刘玉华 医学论坛网

ECCMIDHPV感染病
关注

　　在今年的欧洲临床微生物学与感染病大会（ECCMID）上，部分学者报告了他们在疾病机制方面的新研究，在此，我们作个简要报道。　　 　　男性和女性HPV感染者中HPV自发清除率存在差异 　　人乳头状瘤病毒（HPV）是子宫颈癌和肝门癌的一个危险因素，有时HPV可自发清除。 　　一项研究观察了一年后哪些HPV株较易清除。研究人员分析了来自健康女性的子宫颈样本和来自免疫系统较差男性的肛门样本。他们

　　在今年的欧洲临床微生物学与感染病大会（ECCMID）上，部分学者报告了他们在疾病机制方面的新研究，在此，我们作个简要报道。　　 　　男性和女性HPV感染者中HPV自发清除率存在差异 　　人乳头状瘤病毒（HPV）是子宫颈癌和肝门癌的一个危险因素，有时HPV可自发清除。 　　一项研究观察了一年后哪些HPV株较易清除。研究人员分析了来自健康女性的子宫颈样本和来自免疫系统较差男性的肛门样本。他们发现男性和女性受试者中存在不同的HPV株，除了一被称为HPV-31的菌株外，病毒趋向于在男性受试者中“停留”更长的时间。 　　由于免疫缺陷患者肛门样本较女性子宫颈样本的HPV-31自发清除更频繁，这可能提示该HPV株在身体中持续的机制不一样，或激发了不同的免疫系统应答。保持较高感染病例比例的血清型可能是HPV-11，而不是HPV-31。HPV-11是低危血清型，HPV-31是高危血清型。这些差异是由于黏膜组织类型不同还是由于免疫应答程度不同所致呢？这需要进一步评估。 　　详情点击：Different rates of spontaneous clearance of HPV infections i

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2029250, encodeId=0f0c2029250ef, content=<a href='/topic/show?id=56b7e068271' target=_blank style='color:#2F92EE;'>#疾病机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70682, encryptionId=56b7e068271, topicName=疾病机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Tue Jul 12 12:29:00 CST 2011, time=2011-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655312, encodeId=24031655312a1, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Thu Nov 03 00:29:00 CST 2011, time=2011-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665821, encodeId=53ae166582150, content=<a href='/topic/show?id=978d53318de' target=_blank style='color:#2F92EE;'>#感染性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53318, encryptionId=978d53318de, topicName=感染性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97fa26021282, createdName=12498fa0m19暂无昵称, createdTime=Tue Dec 27 13:29:00 CST 2011, time=2011-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675454, encodeId=96e316e5454c4, content=<a href='/topic/show?id=12f9648099' target=_blank style='color:#2F92EE;'>#ECCMID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6480, encryptionId=12f9648099, topicName=ECCMID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac9827230905, createdName=shalley75, createdTime=Thu Nov 03 05:29:00 CST 2011, time=2011-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056076, encodeId=1f8420560e67d, content=<a href='/topic/show?id=88e6581097d' target=_blank style='color:#2F92EE;'>#新动态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58109, encryptionId=88e6581097d, topicName=新动态)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Mon Oct 10 08:29:00 CST 2011, time=2011-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954186, encodeId=a5e01954186d2, content=<a href='/topic/show?id=3eb664e988' target=_blank style='color:#2F92EE;'>#ECC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6479, encryptionId=3eb664e988, topicName=ECC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Feb 19 15:29:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056102, encodeId=30f120561028f, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 01 12:29:00 CST 2011, time=2011-09-01, status=1, ipAttribution=)]
    2011-07-12 h.y200607_23674418

    #疾病机制#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2029250, encodeId=0f0c2029250ef, content=<a href='/topic/show?id=56b7e068271' target=_blank style='color:#2F92EE;'>#疾病机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70682, encryptionId=56b7e068271, topicName=疾病机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Tue Jul 12 12:29:00 CST 2011, time=2011-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655312, encodeId=24031655312a1, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Thu Nov 03 00:29:00 CST 2011, time=2011-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665821, encodeId=53ae166582150, content=<a href='/topic/show?id=978d53318de' target=_blank style='color:#2F92EE;'>#感染性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53318, encryptionId=978d53318de, topicName=感染性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97fa26021282, createdName=12498fa0m19暂无昵称, createdTime=Tue Dec 27 13:29:00 CST 2011, time=2011-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675454, encodeId=96e316e5454c4, content=<a href='/topic/show?id=12f9648099' target=_blank style='color:#2F92EE;'>#ECCMID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6480, encryptionId=12f9648099, topicName=ECCMID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac9827230905, createdName=shalley75, createdTime=Thu Nov 03 05:29:00 CST 2011, time=2011-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056076, encodeId=1f8420560e67d, content=<a href='/topic/show?id=88e6581097d' target=_blank style='color:#2F92EE;'>#新动态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58109, encryptionId=88e6581097d, topicName=新动态)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Mon Oct 10 08:29:00 CST 2011, time=2011-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954186, encodeId=a5e01954186d2, content=<a href='/topic/show?id=3eb664e988' target=_blank style='color:#2F92EE;'>#ECC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6479, encryptionId=3eb664e988, topicName=ECC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Feb 19 15:29:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056102, encodeId=30f120561028f, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 01 12:29:00 CST 2011, time=2011-09-01, status=1, ipAttribution=)]
    2011-11-03 charl1234575

    #感染性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2029250, encodeId=0f0c2029250ef, content=<a href='/topic/show?id=56b7e068271' target=_blank style='color:#2F92EE;'>#疾病机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70682, encryptionId=56b7e068271, topicName=疾病机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Tue Jul 12 12:29:00 CST 2011, time=2011-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655312, encodeId=24031655312a1, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Thu Nov 03 00:29:00 CST 2011, time=2011-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665821, encodeId=53ae166582150, content=<a href='/topic/show?id=978d53318de' target=_blank style='color:#2F92EE;'>#感染性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53318, encryptionId=978d53318de, topicName=感染性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97fa26021282, createdName=12498fa0m19暂无昵称, createdTime=Tue Dec 27 13:29:00 CST 2011, time=2011-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675454, encodeId=96e316e5454c4, content=<a href='/topic/show?id=12f9648099' target=_blank style='color:#2F92EE;'>#ECCMID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6480, encryptionId=12f9648099, topicName=ECCMID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac9827230905, createdName=shalley75, createdTime=Thu Nov 03 05:29:00 CST 2011, time=2011-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056076, encodeId=1f8420560e67d, content=<a href='/topic/show?id=88e6581097d' target=_blank style='color:#2F92EE;'>#新动态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58109, encryptionId=88e6581097d, topicName=新动态)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Mon Oct 10 08:29:00 CST 2011, time=2011-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954186, encodeId=a5e01954186d2, content=<a href='/topic/show?id=3eb664e988' target=_blank style='color:#2F92EE;'>#ECC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6479, encryptionId=3eb664e988, topicName=ECC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Feb 19 15:29:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056102, encodeId=30f120561028f, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 01 12:29:00 CST 2011, time=2011-09-01, status=1, ipAttribution=)]
    2011-12-27 12498fa0m19暂无昵称

    #感染性疾病#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2029250, encodeId=0f0c2029250ef, content=<a href='/topic/show?id=56b7e068271' target=_blank style='color:#2F92EE;'>#疾病机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70682, encryptionId=56b7e068271, topicName=疾病机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Tue Jul 12 12:29:00 CST 2011, time=2011-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655312, encodeId=24031655312a1, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Thu Nov 03 00:29:00 CST 2011, time=2011-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665821, encodeId=53ae166582150, content=<a href='/topic/show?id=978d53318de' target=_blank style='color:#2F92EE;'>#感染性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53318, encryptionId=978d53318de, topicName=感染性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97fa26021282, createdName=12498fa0m19暂无昵称, createdTime=Tue Dec 27 13:29:00 CST 2011, time=2011-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675454, encodeId=96e316e5454c4, content=<a href='/topic/show?id=12f9648099' target=_blank style='color:#2F92EE;'>#ECCMID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6480, encryptionId=12f9648099, topicName=ECCMID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac9827230905, createdName=shalley75, createdTime=Thu Nov 03 05:29:00 CST 2011, time=2011-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056076, encodeId=1f8420560e67d, content=<a href='/topic/show?id=88e6581097d' target=_blank style='color:#2F92EE;'>#新动态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58109, encryptionId=88e6581097d, topicName=新动态)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Mon Oct 10 08:29:00 CST 2011, time=2011-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954186, encodeId=a5e01954186d2, content=<a href='/topic/show?id=3eb664e988' target=_blank style='color:#2F92EE;'>#ECC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6479, encryptionId=3eb664e988, topicName=ECC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Feb 19 15:29:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056102, encodeId=30f120561028f, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 01 12:29:00 CST 2011, time=2011-09-01, status=1, ipAttribution=)]
    2011-11-03 shalley75

    #ECCMID#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2029250, encodeId=0f0c2029250ef, content=<a href='/topic/show?id=56b7e068271' target=_blank style='color:#2F92EE;'>#疾病机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70682, encryptionId=56b7e068271, topicName=疾病机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Tue Jul 12 12:29:00 CST 2011, time=2011-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655312, encodeId=24031655312a1, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Thu Nov 03 00:29:00 CST 2011, time=2011-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665821, encodeId=53ae166582150, content=<a href='/topic/show?id=978d53318de' target=_blank style='color:#2F92EE;'>#感染性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53318, encryptionId=978d53318de, topicName=感染性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97fa26021282, createdName=12498fa0m19暂无昵称, createdTime=Tue Dec 27 13:29:00 CST 2011, time=2011-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675454, encodeId=96e316e5454c4, content=<a href='/topic/show?id=12f9648099' target=_blank style='color:#2F92EE;'>#ECCMID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6480, encryptionId=12f9648099, topicName=ECCMID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac9827230905, createdName=shalley75, createdTime=Thu Nov 03 05:29:00 CST 2011, time=2011-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056076, encodeId=1f8420560e67d, content=<a href='/topic/show?id=88e6581097d' target=_blank style='color:#2F92EE;'>#新动态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58109, encryptionId=88e6581097d, topicName=新动态)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Mon Oct 10 08:29:00 CST 2011, time=2011-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954186, encodeId=a5e01954186d2, content=<a href='/topic/show?id=3eb664e988' target=_blank style='color:#2F92EE;'>#ECC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6479, encryptionId=3eb664e988, topicName=ECC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Feb 19 15:29:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056102, encodeId=30f120561028f, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 01 12:29:00 CST 2011, time=2011-09-01, status=1, ipAttribution=)]
    2011-10-10 yese

    #新动态#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2029250, encodeId=0f0c2029250ef, content=<a href='/topic/show?id=56b7e068271' target=_blank style='color:#2F92EE;'>#疾病机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70682, encryptionId=56b7e068271, topicName=疾病机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Tue Jul 12 12:29:00 CST 2011, time=2011-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655312, encodeId=24031655312a1, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Thu Nov 03 00:29:00 CST 2011, time=2011-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665821, encodeId=53ae166582150, content=<a href='/topic/show?id=978d53318de' target=_blank style='color:#2F92EE;'>#感染性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53318, encryptionId=978d53318de, topicName=感染性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97fa26021282, createdName=12498fa0m19暂无昵称, createdTime=Tue Dec 27 13:29:00 CST 2011, time=2011-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675454, encodeId=96e316e5454c4, content=<a href='/topic/show?id=12f9648099' target=_blank style='color:#2F92EE;'>#ECCMID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6480, encryptionId=12f9648099, topicName=ECCMID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac9827230905, createdName=shalley75, createdTime=Thu Nov 03 05:29:00 CST 2011, time=2011-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056076, encodeId=1f8420560e67d, content=<a href='/topic/show?id=88e6581097d' target=_blank style='color:#2F92EE;'>#新动态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58109, encryptionId=88e6581097d, topicName=新动态)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Mon Oct 10 08:29:00 CST 2011, time=2011-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954186, encodeId=a5e01954186d2, content=<a href='/topic/show?id=3eb664e988' target=_blank style='color:#2F92EE;'>#ECC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6479, encryptionId=3eb664e988, topicName=ECC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Feb 19 15:29:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056102, encodeId=30f120561028f, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 01 12:29:00 CST 2011, time=2011-09-01, status=1, ipAttribution=)]
    2012-02-19 仁医06

    #ECC#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2029250, encodeId=0f0c2029250ef, content=<a href='/topic/show?id=56b7e068271' target=_blank style='color:#2F92EE;'>#疾病机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70682, encryptionId=56b7e068271, topicName=疾病机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Tue Jul 12 12:29:00 CST 2011, time=2011-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655312, encodeId=24031655312a1, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Thu Nov 03 00:29:00 CST 2011, time=2011-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665821, encodeId=53ae166582150, content=<a href='/topic/show?id=978d53318de' target=_blank style='color:#2F92EE;'>#感染性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53318, encryptionId=978d53318de, topicName=感染性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97fa26021282, createdName=12498fa0m19暂无昵称, createdTime=Tue Dec 27 13:29:00 CST 2011, time=2011-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675454, encodeId=96e316e5454c4, content=<a href='/topic/show?id=12f9648099' target=_blank style='color:#2F92EE;'>#ECCMID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6480, encryptionId=12f9648099, topicName=ECCMID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac9827230905, createdName=shalley75, createdTime=Thu Nov 03 05:29:00 CST 2011, time=2011-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056076, encodeId=1f8420560e67d, content=<a href='/topic/show?id=88e6581097d' target=_blank style='color:#2F92EE;'>#新动态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58109, encryptionId=88e6581097d, topicName=新动态)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Mon Oct 10 08:29:00 CST 2011, time=2011-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954186, encodeId=a5e01954186d2, content=<a href='/topic/show?id=3eb664e988' target=_blank style='color:#2F92EE;'>#ECC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6479, encryptionId=3eb664e988, topicName=ECC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Feb 19 15:29:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056102, encodeId=30f120561028f, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 01 12:29:00 CST 2011, time=2011-09-01, status=1, ipAttribution=)]
    2011-09-01 hbwxf

    #机制研究#

    0